Walleye Capital LLC Takes $98,000 Position in InfuSystem Holdings, Inc. (NYSE:INFU)

Walleye Capital LLC acquired a new stake in InfuSystem Holdings, Inc. (NYSE:INFU) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 11,620 shares of the company’s stock, valued at approximately $98,000. Walleye Capital LLC owned 0.05% of InfuSystem at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of INFU. First Eagle Investment Management LLC grew its position in InfuSystem by 25.9% during the 4th quarter. First Eagle Investment Management LLC now owns 908,371 shares of the company’s stock worth $7,676,000 after acquiring an additional 186,668 shares during the last quarter. JPMorgan Chase & Co. grew its position in InfuSystem by 283.5% during the 4th quarter. JPMorgan Chase & Co. now owns 59,662 shares of the company’s stock worth $504,000 after acquiring an additional 44,106 shares during the last quarter. Barclays PLC boosted its position in InfuSystem by 300.5% in the 3rd quarter. Barclays PLC now owns 28,597 shares of the company’s stock valued at $192,000 after buying an additional 21,457 shares during the last quarter. WINTON GROUP Ltd bought a new position in InfuSystem in the 4th quarter valued at $164,000. Finally, Bank of New York Mellon Corp boosted its position in InfuSystem by 14.3% in the 4th quarter. Bank of New York Mellon Corp now owns 91,219 shares of the company’s stock valued at $771,000 after buying an additional 11,436 shares during the last quarter. 71.13% of the stock is currently owned by institutional investors.

InfuSystem Stock Performance

INFU stock opened at $4.97 on Monday. The business’s fifty day moving average is $5.85 and its 200-day moving average is $7.29. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50. The company has a market cap of $104.45 million, a P/E ratio of 82.85 and a beta of 1.90. InfuSystem Holdings, Inc. has a twelve month low of $4.61 and a twelve month high of $9.97.

Analysts Set New Price Targets

A number of brokerages have commented on INFU. StockNews.com upgraded InfuSystem from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 14th. Sidoti upgraded InfuSystem to a “strong-buy” rating in a research report on Tuesday, March 18th.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.